Page last updated: 2024-12-05
dichlofenthion
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 7328 |
CHEMBL ID | 1396626 |
CHEBI ID | 81730 |
SCHEMBL ID | 117873 |
MeSH ID | M0057757 |
Synonyms (96)
Synonym |
---|
nsc3130 |
phosphorothioic acid, o-(2,4-dichlorophenyl) o,o-diethyl ester |
hexanema |
o,4-dicloro-fenil)-monotiofosfato |
o,4-dichlor-phenyl-monothiophosphat |
o,4-dichlorophenyl) thiophosphate |
2,4-dichlorophenyl diethyl phosphorothionate |
dichlofenthion |
o,4-dichlorophenyl) phosphorothioate |
thiophosphate de o-2,o-diethyle |
ent 17,470 |
o-(2,o-diethyl phosphorothioate |
vc 13 |
wln: gr cg dops & o2 & o2 |
nemacide |
v-c 13 |
nsc-52964 |
97-17-6 |
o-2,o-diethyl phosphorothioate |
o,4-dichloor-fenyl)-monothiofosfaat |
v-c 1-13 |
phosphorothioic acid,4-dichlorophenyl)-o,o-diethyl ester |
dichlofention |
diethyl 2,4-dichlorophenyl phosphorothionate |
o,4-dichlorophenyl)phosphorothioate |
phenol,4-dichloro-, o-ester with o,o-diethyl phosphorothioate |
v-cl 13 |
dichlorofenthion |
v-c-13 |
tri-vc 13 |
phosphorothioic acid,4-dichlorophenyl) o,o-diethyl ester |
nsc52964 |
vc-13 nemacide |
mobilawn |
dichlofenthion [ansi] |
einecs 202-564-5 |
o,o-diaethyl-o-2,4-dichlor-phenyl-monothiophosphat [german] |
2,4-dichloro-phenyl diethyl phosphorothionate |
ecp (pesticide) |
ai3-17470 |
phenol, 2,4-dichloro-, o-ester with o,o-diethyl phosphorothioate |
epa pesticide chemical code 028601 |
o,o-diaethyl-o-2,4-dichlorphenyl-thionophosphat [german] |
thiophosphate de o-2,4-dichlorophenyle et de o,o-diethyle [french] |
ent 17470 |
nsc 52964 |
hsdb 1576 |
nemacide vc-13 |
o,o-dietil-o-(2,4-dicloro-fenil)-monotiofosfato [italian] |
caswell no. 321 |
brn 1993440 |
vc13 nemacide |
o-(2,4-dichlorophenyl)-o,o-diethyl phosphorothioic acid |
o-2,4-dichlorophenyl o,o-diethyl phosphorothioate |
o,o-diethyl o-(2,4-dichlorophenyl) phosphorothioate |
o,o-diethyl-o-(2,4-dichloor-fenyl)-monothiofosfaat [dutch] |
o,o-diethyl o-2,4-dichlorophenyl thiophosphate |
NCGC00166316-01 |
NCGC00166316-02 |
thiophosphate de o-2,4-dichlorophenyle et de o,o-diethyle |
dichlofenthion [ban] |
o,o-diaethyl-o-2,4-dichlorphenyl-thionophosphat |
o,o-diaethyl-o-2,4-dichlor-phenyl-monothiophosphat |
o,o-diethyl-o-(2,4-dichloor-fenyl)-monothiofosfaat |
unii-64234gt8tt |
dichlofenthion [ansi:iso] |
o,o-dietil-o-(2,4-dicloro-fenil)-monotiofosfato |
64234gt8tt , |
C18398 |
NCGC00255058-01 |
dtxcid6020274 |
cas-97-17-6 |
tox21_301160 |
dtxsid8040274 , |
CHEMBL1396626 |
chebi:81730 , |
diclofenthion |
dichlorfenthion |
FT-0603082 |
AKOS015902498 |
SCHEMBL117873 |
o-(2,4-dichlorophenyl) o,o-diethyl thiophosphate # |
o-(2,4-dichlorophenyl) o,o-diethyl phosphorothioate |
o,o-diethyl o-(2,4-dichlorophenyl) thiophosphate |
o-(2,4-dichlorophenyl)o,o-diethylphosphorothionate |
dichlofenthion [hsdb] |
dichlofenthion [iso] |
dichlofenthion [mi] |
dichlofenthion [mart.] |
sr-01000883721 |
SR-01000883721-1 |
dichlofenthion, pestanal(r), analytical standard |
dichlofenthion 10 microg/ml in cyclohexane |
Q3026533 |
(2,4-dichlorophenoxy)-diethoxy-sulfanylidene-lambda5-phosphane |
dichlofenthion 1000 microg/ml in acetone |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
organic thiophosphate | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (11)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 56.2341 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
acetylcholinesterase | Homo sapiens (human) | Potency | 28.2576 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 19.9526 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 54.4827 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 20.3246 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 18.1110 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 21.6899 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 54.4827 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 15.5345 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 50.1187 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 68.5896 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (75.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 27.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.14) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (20.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |